United Therapeutics Corp
NASDAQ:UTHR
Wall Street
Price Targets
UTHR Price Targets Summary
United Therapeutics Corp
According to Wall Street analysts, the average 1-year price target for
UTHR
is 298.098 USD
with a low forecast of 184.83 USD and a high forecast of 393.75 USD.
UTHR Last Price Targets
United Therapeutics Corp
The latest public price target was made on Feb 12, 2024 by
Chris Shibutani
from
Goldman Sachs
,
who expects
UTHR
stock to
drop by 10%
over the next 12 months.
You can read more about this price target by viewing
the article on Benzinga.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Chris Shibutani
Goldman Sachs
|
215
USD
Downside 10% |
2 months ago
Feb 12, 2024
|
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
Benzinga
|
Operating Income
Forecast
Operating Income Estimate
United Therapeutics Corp
For the last 8 years the
compound annual growth rate for
United Therapeutics Corp's operating income is
7%.
The projected
CAGR
for the next 3 years is
10%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is UTHR's stock price target?
Price Target
298.098
USD
According to Wall Street analysts, the average 1-year price target for
UTHR
is 298.098 USD
with a low forecast of 184.83 USD and a high forecast of 393.75 USD.
What is United Therapeutics Corp's Revenue forecast?
Projected CAGR
11%
For the last 8 years the
compound annual growth rate for
United Therapeutics Corp's revenue is
6%.
The projected
CAGR
for the next 3 years is
11%.
What is United Therapeutics Corp's Operating Income forecast?
Projected CAGR
10%
For the last 8 years the
compound annual growth rate for
United Therapeutics Corp's operating income is
7%.
The projected
CAGR
for the next 3 years is
10%.
What is United Therapeutics Corp's Net Income forecast?
Projected CAGR
8%
For the last 8 years the
compound annual growth rate for
United Therapeutics Corp's net income is
5%.
The projected
CAGR
for the next 3 years is
8%.
You don't have any saved screeners yet
